46 - Scientific merits and practical considerations for site-specific susceptibility testing

Speaker(s)

• 

  Elizabeth Hirsch, PharmD

  Associate Professor
  University of Minnesota College of Pharmacy
  Minneapolis, Minnesota

  Disclosure: Merck () : Grant/Research Support; Nabriva Therapeutics () : Advisor or Review Panel member
• 

  Amy Mathers, MD, D(ABMM)

  Associate Professor
  University of Virginia
  Charlottesville, Virginia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Melvin Weinstein, MD

  Emeritus Professor of Medicine and Pathology & Laboratory Medicine
  Medicine
  Rutgers Robert Wood Johnson Medical School
  Princeton Junction, New Jersey

  Disclosure: Clinical & Laboratory Standards Institute : Committee Chair, receive expense reimbursement only (Status: Ongoing), Other Financial or Material Support (Status: Ongoing); First Light Diagnostics : Advisor or Review Panel member (Status: Ongoing); Helixbind, Inc. : Advisor or Review Panel member (Status: Ongoing); Safeguard Biosystems : Advisor or Review Panel member (Status: Ongoing); SeLux Diagnostics : Consultant (Status: Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: 0221-9999-20-482-H04-P

Learning Objectives:

• describe challenges in susceptibility testing in contemporary laboratory settings
• utilize laboratory results to optimize patient care
• explain the process for CLSI breakpoint changes

Presentations:

• 2:45pm – 4:00pm EDT

  Implementation Hurdles
  Amy J. Mathers, MD, D(ABMM) – University of Virginia
• 2:45pm – 4:00pm EDT

  Pharmacological Considerations
  Elizabeth B. Hirsch, PharmD – University of Minnesota College of Pharmacy
• 2:45pm – 4:00pm EDT

  Process for Setting and Revising Susceptibility Breakpoints by CLSI
  Melvin P. Weinstein, MD – Rutgers Robert Wood Johnson Medical School